DK1294893T3 - Modifikation af hepatitis B-kerneantigen - Google Patents
Modifikation af hepatitis B-kerneantigenInfo
- Publication number
- DK1294893T3 DK1294893T3 DK01943625T DK01943625T DK1294893T3 DK 1294893 T3 DK1294893 T3 DK 1294893T3 DK 01943625 T DK01943625 T DK 01943625T DK 01943625 T DK01943625 T DK 01943625T DK 1294893 T3 DK1294893 T3 DK 1294893T3
- Authority
- DK
- Denmark
- Prior art keywords
- hepatitis
- hbcag
- protein
- core antigen
- modification
- Prior art date
Links
- 101710132601 Capsid protein Proteins 0.000 title abstract 6
- 208000002672 hepatitis B Diseases 0.000 title abstract 2
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 235000018102 proteins Nutrition 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 239000004475 Arginine Substances 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0015308A GB0015308D0 (en) | 2000-06-22 | 2000-06-22 | Modification of hepatitis B core antigen |
| GB0024544A GB0024544D0 (en) | 2000-10-06 | 2000-10-06 | Modification of hepatitus B core antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1294893T3 true DK1294893T3 (da) | 2006-07-03 |
Family
ID=26244528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01943625T DK1294893T3 (da) | 2000-06-22 | 2001-06-22 | Modifikation af hepatitis B-kerneantigen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040054139A1 (fr) |
| EP (1) | EP1294893B1 (fr) |
| JP (1) | JP2004500868A (fr) |
| AT (1) | ATE320493T1 (fr) |
| AU (2) | AU2001266163B2 (fr) |
| CA (1) | CA2413546C (fr) |
| DE (1) | DE60117978T2 (fr) |
| DK (1) | DK1294893T3 (fr) |
| ES (1) | ES2260235T3 (fr) |
| PT (1) | PT1294893E (fr) |
| WO (1) | WO2001098333A2 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001027281A1 (fr) * | 1999-10-08 | 2001-04-19 | Celltech Pharma Europe Limited | Conception d'immunogenes |
| KR100808313B1 (ko) * | 2000-04-07 | 2008-02-27 | 유니버시티 오브 리즈 이노베이션즈 리미티드 | 비형 간염 코어 항원 융합 단백질 |
| US6942866B2 (en) | 2000-08-16 | 2005-09-13 | Apovia, Inc. | Malaria immunogen and vaccine |
| CU23002A1 (es) * | 2000-12-01 | 2004-11-18 | Ct Ingenieria Genetica Biotech | Método de obtención de agregados antigénicos y su uso en formulaciones |
| US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| US7361352B2 (en) * | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| US20030202982A1 (en) * | 2001-08-15 | 2003-10-30 | Birkett Ashley J. | Influenza immunogen and vaccine |
| US20040146524A1 (en) * | 2002-02-21 | 2004-07-29 | Katelynne Lyons | Stabilized immunogenic HBc chimer particles |
| ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
| BR0213117A (pt) | 2001-10-05 | 2004-09-21 | Cytos Biotechnology Ag | Conjugados peptìdeo angiotensina-veìculo e seus usos |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
| WO2003072731A2 (fr) * | 2002-02-21 | 2003-09-04 | Apovia, Inc. | Particules chimeres hbc stabilisees ayant des immunogenes meningoques |
| EP2392345A3 (fr) | 2002-07-18 | 2012-03-07 | Cytos Biotechnology AG | Conjugués vecteurs d'haptène comportant des particules de type viral et utilisations associées |
| RU2450827C2 (ru) | 2002-07-19 | 2012-05-20 | Цитос Биотехнологи Аг | Композиции вакцин, содержащие наборы антигенов в виде амилоида бета 1-6 |
| JP5022028B2 (ja) | 2003-03-26 | 2012-09-12 | サイトス・バイオテクノロジー・アクチェンゲゼルシャフト | メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| AU2004260665B2 (en) | 2003-07-30 | 2007-11-15 | Vlp Biotech, Inc. | Hepatitis virus core proteins as vaccine platforms and methods of use thereof |
| US7320795B2 (en) | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| US7144712B2 (en) | 2003-07-30 | 2006-12-05 | Vaccine Research Institute Of San Diego | Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| EP1694301A4 (fr) * | 2003-12-02 | 2009-11-18 | Cytimmune Sciences Inc | Procedes et compositions de production d'anticorps monoclonaux |
| EP1764369A1 (fr) | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vaccins comprenant la protéine du noyau du HBV tronquée ainsi qu'un adjuvant à base de saponine |
| EP2219458B1 (fr) * | 2007-11-08 | 2015-07-15 | Cytimmune Sciences, Inc. | Compositions et procédés de production d'anticorps |
| EP2865389A1 (fr) | 2008-12-09 | 2015-04-29 | Pfizer Vaccines LLC | Vaccin peptidique IgE CH3 |
| MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
| ES2670576T3 (es) | 2009-09-03 | 2018-05-31 | Pfizer Vaccines Llc | Vacuna de PCSK9 |
| CA2800774A1 (fr) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Vaccin peptidique ige ch3 |
| WO2012131504A1 (fr) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Vaccin à base de pcsk9 |
| KR102190180B1 (ko) | 2011-04-15 | 2020-12-11 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | Ｄｎａ 백신 |
| WO2014034735A1 (fr) | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Vaccin à base d'adn contenant un épitope spécifique du vegf et/ou un épitope spécifique de l'angiopoïétine-2 |
| JP6001974B2 (ja) | 2012-09-21 | 2016-10-05 | アンジェスＭｇ株式会社 | アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン |
| CN104341506A (zh) * | 2013-07-30 | 2015-02-11 | 复旦大学 | 一种重组融合蛋白及其用途 |
| US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
| JPWO2015133467A1 (ja) * | 2014-03-06 | 2017-04-06 | 株式会社シノテスト | Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質 |
| AU2019231654B2 (en) | 2018-03-06 | 2025-12-11 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| AU2019231652B2 (en) | 2018-03-06 | 2025-05-22 | Precigen, Inc. | Hepatitis B vaccines and uses of the same |
| CN112105733B (zh) | 2018-04-19 | 2024-10-29 | 查美特制药公司 | 合成rig-i样受体激动剂 |
| CN113508125A (zh) * | 2018-12-28 | 2021-10-15 | 小利兰·斯坦福大学托管委员会 | 工程化乙型肝炎核心多肽 |
| CA3149415A1 (fr) | 2019-08-29 | 2021-03-11 | Eric Bruening | Vaccins contre le virus de l'hepatite b |
| EP4458975A3 (fr) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Vaccins contre le vhb et méthodes de traitement du vhb |
| AU2021301953B2 (en) * | 2020-07-01 | 2025-01-02 | Institute Of Biophysics, Chinese Academy Of Sciences | Construction and application of fusion protein vaccine platform |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ235315A (en) * | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
| ES2257879T3 (es) * | 1998-11-05 | 2006-08-01 | Powderject Vaccines, Inc. | Productos de recombinacion de acido nucleico para inmunizacion genetica. |
-
2001
- 2001-06-22 US US10/312,045 patent/US20040054139A1/en not_active Abandoned
- 2001-06-22 PT PT01943625T patent/PT1294893E/pt unknown
- 2001-06-22 AU AU2001266163A patent/AU2001266163B2/en not_active Ceased
- 2001-06-22 ES ES01943625T patent/ES2260235T3/es not_active Expired - Lifetime
- 2001-06-22 DE DE60117978T patent/DE60117978T2/de not_active Expired - Lifetime
- 2001-06-22 WO PCT/GB2001/002817 patent/WO2001098333A2/fr not_active Ceased
- 2001-06-22 AU AU6616301A patent/AU6616301A/xx active Pending
- 2001-06-22 DK DK01943625T patent/DK1294893T3/da active
- 2001-06-22 EP EP01943625A patent/EP1294893B1/fr not_active Expired - Lifetime
- 2001-06-22 CA CA2413546A patent/CA2413546C/fr not_active Expired - Fee Related
- 2001-06-22 AT AT01943625T patent/ATE320493T1/de not_active IP Right Cessation
- 2001-06-22 JP JP2002504288A patent/JP2004500868A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001098333A2 (fr) | 2001-12-27 |
| WO2001098333A3 (fr) | 2002-03-28 |
| ES2260235T3 (es) | 2006-11-01 |
| EP1294893A2 (fr) | 2003-03-26 |
| DE60117978T2 (de) | 2006-11-02 |
| CA2413546C (fr) | 2011-06-14 |
| CA2413546A1 (fr) | 2001-12-27 |
| DE60117978D1 (de) | 2006-05-11 |
| ATE320493T1 (de) | 2006-04-15 |
| EP1294893B1 (fr) | 2006-03-15 |
| US20040054139A1 (en) | 2004-03-18 |
| AU2001266163B2 (en) | 2006-07-13 |
| JP2004500868A (ja) | 2004-01-15 |
| AU6616301A (en) | 2002-01-02 |
| PT1294893E (pt) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1294893T3 (da) | Modifikation af hepatitis B-kerneantigen | |
| DK1362109T3 (da) | Rekombinante oligomere protein-komplekser med foröget immunogent potentiale | |
| EA200300129A1 (ru) | Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах | |
| BG98523A (en) | Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b | |
| NZ545048A (en) | Chimeric antigens for breaking host tolerance to foreign antigens | |
| DE60039715D1 (de) | Hcv-impfstoff zusammensetzungen | |
| EA200801798A1 (ru) | Виросомоподобные везикулы, содержащие антигены, производные от gp41 | |
| EA200201077A1 (ru) | Коровые антигенные химерные белки гепатита в | |
| DE60138014D1 (de) | Chimäre arterivirus-ähnliche partikel | |
| TW200503752A (en) | HCV vaccines | |
| ATE323758T1 (de) | Attenuierte lebendimpfstoffe | |
| WO2004004761A3 (fr) | Particule virale d'adjuvant | |
| DE60234085D1 (de) | Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor | |
| ATE283066T1 (de) | Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp) | |
| DK0551275T3 (da) | Non-A non-B sekvenser | |
| HK1052368A1 (zh) | 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構 | |
| ATE409705T1 (de) | Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs | |
| WO2001092311A3 (fr) | Bibliotheques peptidiques combinatoires convergentes et leur applicaton a la vaccination contre le virus de l'hepatite c | |
| WO2002000252A3 (fr) | Tolerance et virus de l'hepatite c chronique | |
| SE0002498D0 (sv) | Papillomavirus vaccine | |
| AU4394101A (en) | A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide | |
| DK1237571T3 (da) | Toscana-virus-nukleinprotein |